Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development
International Journal of Molecular Sciences · 26.02.2024 · 25 (5) · 2682
DOI: 10.3390/ijms25052682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.02.2024. Verfasst von Eunji Jeong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Idiopathic Pulmonary Fibrosis, Antirheumatic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by swelling in at least one joint. Owing to an overactive immune response, extra-articular manifestations are observed in certain cases, with interstitial lung disease (ILD) being the most common. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is characterized by chronic inflammation of the interstitial space, which causes fibrosis and the scarring of lung tissue. Controlling inflammation and pulmonary fibrosis in RA-ILD is important because they are associated with high morbidity and mortality. Pirfenidone and nintedanib are specific drugs against idiopathic pulmonary fibrosis and showed efficacy against RA-ILD in several clinical trials. Immunosuppressants and disease-modifying antirheumatic drugs (DMARDs) with anti-fibrotic effects have also been used to treat RA-ILD. Immunosuppressants moderate the overexpression of cytokines and immune cells to reduce pulmonary damage and slow the progression of fibrosis. DMARDs with mild anti-fibrotic effects target specific fibrotic pathways to regulate fibrogenic cellular activity, extracellular matrix homeostasis, and oxidative stress levels. Therefore, specific medications are required to effectively treat RA-ILD. In this review, the commonly used RA-ILD treatments are discussed based on their molecular mechanisms and clinical trial results. In addition, a computational approach is proposed to develop specific drugs for RA-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Yale College, Yale University, New Haven, CT 06520, USA.
- Department of Clinical Pharmacology and Therapeutics, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul 02447, Republic of Korea.
- East-West Bone & Joint Disease Research Institute, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.
ORCID-Profile: Eunji Jeong, Hyunseok Hong, Yeon-Ah Lee
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
Zitieren
APA
Jeong, E., Hong, H., Lee, Y. A., & Kim, K. S. (2024). Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development. International Journal of Molecular Sciences, 25(5), 2682. https://doi.org/10.3390/ijms25052682
Vancouver
Jeong E, Hong H, Lee YA, Kim KS. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development. International Journal of Molecular Sciences. 2024;25(5):2682. doi:10.3390/ijms25052682
BibTeX
@article{Jeong2024,
author = {Jeong, Eunji and Hong, Hyunseok and Lee, Yeon-Ah and Kim, Kyoung-Soo},
title = {Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {5},
pages = {2682},
doi = {10.3390/ijms25052682}
}
EUVIMED